Poonawalla Fincorp Limited has informed the Exchange about Credit Rating
POONAWALLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CARE Ratings has reaffirmed Poonawalla Fincorp's highest investment-grade ratings — CARE AAA (Stable) on long-term bank facilities and CARE A1+ on short-term facilities and commercial paper. The rating action also includes a new assignment of AAA to ₹750 crore subordinate debt and ₹8,000 crore non-convertible debentures, with total long-term bank facilities enhanced from ₹20,775.65 crore to ₹26,731.30 crore. The ratings factor in strong parent support from the Cyrus Poonawalla group (62.53% stake via Rising Sun Holdings), whose flagship Serum Institute of India is a global vaccine leader. The company saw its loan book (AUM) grow to ₹35,631 crore in FY25 from ₹25,003 crore in FY24, though profitability took a hit with a small net loss of ₹98.34 crore due to higher credit costs from stress in the legacy small-ticket personal loan book.
Reaffirmation of AAA/A1+ ratings reflects strong creditor confidence and continued access to low-cost funds, supporting future growth. Shareholders can take comfort from the robust promoter backing, but should watch the rising gearing (3.28x in FY25 vs 1.90x in FY24) and the FY25 loss as the company invests in scaling new product lines.